Loading clinical trials...
Loading clinical trials...
A Phase II Evaluation of Sunitinib Malate (Sutent®, SU11248, NCI-Supplied Agent , NSC # 736511) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Conditions
Interventions
sunitinib malate
Locations
1
United States
Gynecologic Oncology Group
Philadelphia, Pennsylvania, United States
Start Date
October 1, 2006
Primary Completion Date
June 1, 2007
Completion Date
January 1, 2010
Last Updated
July 23, 2019
NCT07467772
NCT01846520
NCT00659360
NCT01155258
NCT00390234
NCT00245102
Lead Sponsor
National Cancer Institute (NCI)
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions